Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of KN3835 for Flexible/Semi-flexible Hammertoe
NCT07846280Phase 3Not yet recruiting
- Sponsor
- Keenova Therapeutics
- Start
- Oct 2026
- Primary completion
- Dec 2028
01
Overview
Phase 3, double-blind trial of collagenase clostridium histolyticum in hammertoe (2 arms), sponsored by Keenova Therapeutics. Primary endpoint: Number of Participants with Adverse Events at Day 360. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
collagenase clostridium histolyticum
03
Conditions
hammertoe
Beyond the preview
Go deeper on NCT07846280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07846280.